The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | BOREAS trial: disease-modifying activity of navtemadlin in JAK-inhibitor R/R myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the promising results of the Phase III BOREAS trial (NCT03662126) comparing navtemadlin with best available therapy (BAT) in relapsed/refractory (R/R) patients with myelofibrosis (MF). Dr Bose highlights that, in this trial, navtemadlin appears to profoundly affect several biomarkers believed to be markers of disease modification in MF, solidifying its potential as an efficacious treatment option in patients with the disease. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
